May 21, 2009 - Boston Scientific Corp. this week announced results from an analysis of economic and quality of ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
May 22, 2009
May 22, 2009 - New data presented yesterday at EuroPCR from an international, post-approval, single-arm study ...
May 21, 2009
May 8, 2009 - Preliminary data presented yesterday at the 32nd annual SCAI Scientific Sessions show that 82 ...
May 08, 2009April 20, 2009 - Boston Scientific recently disclosed the Court of Appeals for the Federal Circuit upheld the ...
April 20, 2009
April 16, 2009 -Twelve-month data from the ZEST trial presented at ACC 2009 showed the Endeavor Drug-Eluting Stent ...
April 16, 2009
April 10, 2009 - The results of the ZEST randomized controlled trial released at ACC 2009 showed the Cypher ...
April 10, 2009
April 3, 2009 - Long-term data presented at ACC.09 from Abbott’s SPIRIT II clinical trial demonstrated the ...
April 03, 2009March 30, 2009 - An AHRQ-funded study finds a lower risk of death and heart attack in heart disease patients 65 ...
March 30, 2009
March 16, 2009 - Cordis Corp. said today it plans to launch a global, head-to-head, randomized clinical trial ...
March 16, 2009
March 12, 2009 - CeloNova BioSciences Inc. said yesterday physicians performing a live stent implantation during ...
March 12, 2009
March 5, 2009 - In the first six-year follow-up of a pivotal study of any drug-eluting stent, the clinical ...
March 05, 2009
March 3, 2009 - Boston Scientific Corp. today said it launched its TAXUS Liberté Paclitaxel-Eluting Coronary Stent ...
March 03, 2009
February 19, 2009 - The New England Journal of Medicine this week published the results from the SYNTAX trial, in ...
February 19, 2009
February 16 - The CYPHER SELECT Plus Sirolimus-eluting Coronary Stent has received CE marking within the European ...
February 16, 2009
Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in ...
February 10, 2009© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now